ANT-GROUP-DIGITAL
3.11.2022 10:19:44 CET | Business Wire | Press release
Ant Group Digital Technologies, a digital technology provider under Ant Group, today unveiled its blockchain storage engine “LETUS” (Log-structured Efficient Trusted Universal Storage) at the Apsara Conference 2022 in Hangzhou.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221103005680/en/
Yan Ying, Technical Director of AntChain, unveiled the LETUS at the Apsara Conference (Photo: Business Wire)
LETUS, which was developed and designed by the AntChain team, will increase the effectiveness and lower the storage costs for blockchain networks.
Blockchain is a distributed peer-to-peer network, with each node storing data such as blocks and states. The LETUS storage engine is deployed at each blockchain node to provide trusted storage support. At the same time, LETUS has the advantages in performance, large scale workloads handling capability, cost, and resource efficiency through Smart Thermo-control Tiering and Boundary Scan Based Batch Pruning.
“As more and more digital assets are stored on the blockchain, storage capacity and efficiency has increasing impact on the overall performance of blockchain platforms, including transaction speeds and operational costs,” said Yan Ying, Technical Director of AntChain. “Compared to current mainstream industry solutions, LETUS can improve storage throughput by 15 times, reduce latency by 90%, and save disk bandwidth and space usage by 95% and 60%, respectively."
LETUS has already been deployed and running in Topnod, a digital collectibles platform powered by AntChain. It has helped the platform greatly improve performance and reduce storage costs by about 75%.
“For the many industries undergoing digital transformations, mutual trust between companies and customers is increasingly important. At Ant, we have been investing in research and development for blockchain and other digital technologies that help to increase both trust and security,” said Geoff Jiang, President of Digital Technology Business Group at Ant Group. “We remain focused on the technological breakthroughs that create a trusted digital network to improve industrial collaboration and allow us to use our innovative products and services to better serve the real economy.”
During the conference, Ant Group Digital Technologies also released the:
- 4.0 version of mPaaS, its one-stop mobile development solution;
- 2.0 version of its Morse MPC (Multi-party Computation) platform;
- 4.0 version of SOFAStack, its cloud-native PaaS platform;
- 4.0 version of OceanBase Community Edition, its distributed database; and
- other security products.
In the past two years, Ant Group Digital Technologies has also released a number of blockchain-related products and solutions, including:
- AntChain Station, the all-in-one workstation;
- Blockchain Transmission Network (BTN), a high-speed, long-distance blockchain communication technology;
- Module-as-a-Service (MaaS) integrated computing module for simplified blockchain deployment;
- FAIR, the data privacy collaboration platform; and
- T1 security chip, its self-developed blockchain-powered security chip.
Many of these cutting-edge solutions have been successfully deployed by Chery Automobile, Zhejiang Huatie Emergency Equipment Science and Technology and other industry partners.
Ant Group Digital Technologies
Ant Group Digital Technologies continues to promote the development and application of digital technology, introducing leading products like AntChain, OceanBase, SOFAStack, and mPaaS based on its expertise in blockchain, privacy computing, security technology, and distributed database. Ant Group Digital Technologies is committed to working with partners across different industries to support the small and medium-sized financial institutions in their digital transformation, enable SMEs in the service industry to operate digitally and facilitate digital collaboration across industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
